Forecast horizon — calibration-scored at resolution.
By 2028, MMA embolization will be incorporated into AANS/CNS guidelines as a recommended adjunct for recurrent cSDH.
Your probability this resolves TRUE
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
1 event · 0 snapshots
Registry data
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.0741
By 2028, ≥40% of cSDH evacuations at academic centers will include adjunctive MMA embolization.
0.1508
The EMBOLISE trial's stated primary conclusion — MMA embolization as an adjunct to surgical evacuation lowers recurrence for symptomatic chronic subdural hematoma. — replicates in independent cohorts.
0.1606
By 2028, flow-diverter use will extend to posterior circulation aneurysms with safety non-inferior to anterior-circulation benchmarks.
0.1614
The MEMBRANE trial's stated primary conclusion — Middle meningeal artery embolization reduces recurrence of chronic subdural hematoma. — replicates in independent cohorts.
0.2018
By 2028, late-window thrombectomy (6–24h) will be explicitly endorsed by AHA/ASA guidelines as standard-of-care in qualifying LVO patients across at least 80% of US comprehensive stroke centers.
0.2108
By 2028, CT-perfusion will be standard at the majority of thrombectomy-capable centers, matching the EXTEND-IA selection criteria.